Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD

Table 2

Results of anti-VEGF therapy in eyes with neovascular age-related macular degeneration.

	Ever-smokers ()	Never-smokers ()
AMD subtype, no. (%)
PCV	20 (56)	11 (39)
tAMD	16 (44)	17 (61)	0.66^‡
Baseline, mean (SD)
VA (logMAR)	0.28 (0.30)	0.37 (0.39)	0.48
Central retinal  thickness (µm)	298.4 (74.1)	342.1 (77.5)	0.02
PCV	310.1 (69.4)	316.5 (93.4)	0.92
tAMD	283.7 (79.4)	358.6 (62.7)	0.004
Subfoveal choroidal  thickness (µm)	255.0 (118.7)	239.2 (96.7)	0.8
Outcome, mean (SD)
VA (logMAR)	0.20 (0.29)	0.29 (0.36)	0.23
Central retinal  thickness (µm)	225.1 (60.2)	241.7 (85.1)	0.56
Subfoveal choroidal  thickness (µm)	220.8 (128.8)	201.3 (88.1)	0.90
Change, mean (SD)
VA (logMAR)	−0.07 (0.32)	−0.08 (0.39)	0.82
Central retinal  thickness (µm)	73.2 (85.4)	100.4 (100.2)	0.14
Subfoveal choroidal  thickness (µm)	31.2 (46.6)	38.0 (38.8)	0.67
Follow-up (yrs)	3.6 (2.1)	3.8 (2.0)	0.60
No. of injections (no./yr)	5.9 (2.7)	5.3 (2.6)	0.30
IVR (no./patient)	5.0 (0.2)	6.1 (0.2)
IVA (no./patient)	14.7 (0.3)	14.2 (0.4)	0.75^‡

^‡Chi-square test.